Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
The independent financial analyst theScreener just awarded an improved star rating to NOVAVAX (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date November 19, 2021, the closing price ...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
BERY has positioned itself as a market leader in making plastics greener. This, and the company's steady consolidation of its industry, prime it to maintain its above industry average UAFRS-based (Uniform) ROA and above industry average growth. While the market is pricing returns to collapse to cycle lows, the company's strong strategy is likely to prime it for returns to remain strong going forward. On top of that, management's compensation aligns them to focus specifically on maintaining hig...
Novavax, Inc. (NVAX:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with a 3.1x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, and management may have concerns about vaccine production, global supply chain development, and vaccine efficacy Specifically, management may lack confidence in their ability to sustain revenue growth, fulfill their advance purchase agreements (APAs) on schedule, and secure addit...
Following a new study done at Columbia University showing that the SA Variant could be a bigger threat than previously thought & new CDC guidance which continues to discourage travel, we are further convinced that border restrictions & closures are likely to increase, not decrease as we progress through 2021. We show that previous lab studies of vaccine efficacy against the SA strain may have been overstated. Our analysis shows that 55% of the population could be potentially at risk from the SA ...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Round Trip Back To Resistance Our base case continues to be for near-term consolidation while the market determines the implications of states' reopening (i.e., the “wait-and-see†phase). Until this consolidation period resolves below support or above resistance we are maintaining a relatively neutral stance considering the wide range of outcomes. Below we highlight new developments which remain generally positive. Still, many major indexes are testing logical resistance and until we see br...
ullish Tape Despite Inconsistencies Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight developments that are inconsistent with a major bottom in equities that suggests the broad equity market is not yet out of the woods. · S&P 500 Short-Term Levels. We continue to respect the bullish tape, however the S&P 500 remains in the 2855-2900 resistance zone while forming a bearish rising wedge patt...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.